Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route

Pathak, Rudree; Dash, Ranjeet Prasad; Misra, Manju; Nivsarkar, Manish

doi:10.1016/j.apsb.2014.02.002

Cited by 92 publications

(52 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7). The nasal mucosa is attached to the upper part of the instrument while the lower part is loaded with the formulation (Hägerström and Edsman, 2001;Pathak et al, 2014).…”

Section: Models With Nasal Tissuementioning

confidence: 99%

See 1 more Smart Citation

How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods

Salade

Wauthoz

Goole

et al. 2019

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Nasal delivery offers many benefits over other conventional routes of delivery (e.g. oral or intravenous administration). Benefits include, among others, a fast onset of action, non-invasiveness and direct access to the central nervous system. The nasal cavity is not only limited to local application (e.g. rhinosinusitis) but can also provide direct access to other sites in the body (e.g. the central nervous system or systemic circulation). However, both the anatomy and the physiology of the nose impose their own limitations, such as a small volume for delivery or rapid mucociliary clearance. To meet nasal-specific criteria, the formulator has to complete a plethora of tests, in vitro and ex vivo, to assess the efficacy and tolerance of a new drug-delivery system. Moreover, depending on the desired therapeutic effect, the delivery of the drug should target a specific pathway that could potentially be achieved through a modified release of this drug. Therefore, this review focuses on specific techniques that should be performed when a nasal formulation is developed. The review covers both the tests recommended by regulatory agencies (e.g. the Food and Drug Administration) and other complementary experiments frequently performed in the field.

show abstract

“…7). The nasal mucosa is attached to the upper part of the instrument while the lower part is loaded with the formulation (Hägerström and Edsman, 2001;Pathak et al, 2014).…”

Section: Models With Nasal Tissuementioning

confidence: 99%

“…Carbopol 934P) and thus confirm that it has the same ability to adhere to the mucosa. The formulation was considered as suitable for the nose-tobrain delivery of nimodipine (Pathak et al, 2014).…”

Section: Models With Nasal Tissuementioning

confidence: 99%

How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods

Salade

Wauthoz

Goole

et al. 2019

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…After this time the samples were centrifuged at 3000 rpm for 20 min, then the supernatant layer for each sample filtered by using filter membrane (0.45 µm). After filtration the samples diluted with methanol and the solubility determined at λ max 238nm by using UV-visible spectrophotometer and the measurement was done in triplicate 9 .…”

Section: Solubility Study For Screening Of Componentsmentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

The aim of this study was to develop oil in water nanoemulsion of nimodipine intended for oral use. Nimodipine is a calcium channel blocker that has poor oral bioavailability (3-30%) due to its low solubility and first-pass metabolism. So, nanoemulsion of nimodipine increase its solubility and enhance its oral bioavailability. Pseudo -ternary phase diagrams were made by using aqueous titration method. Nanoemulsions of pseudo-ternary phase diagrams composed of S mix (mixture of surfactant and co-surfactant), oil and deionized water. These nanoemulsions subjected for thermodynamic stability tests in order to select optimized formulations. Nimodipine nanoemulsions were subjected for characterizations studies in order to select the optimized formula. The characterizations studies explain that the optimized formula NE5 composed of 0.6% of nimodipine, 25% of S mix (2:1) that mean (16.66% tween 20: 8.33% PEG400), 10% of oleic acid and 64.4% of deionized water. The optimized formula NE5 characterized by droplet size (50 -81.2 nm), polydispersity index (0.01), pH value (6.51), higher zeta potential (-45.6 mV), drug content (98.9%), low viscosity and in vitro release of nimodipine was significantly higher (P<0.05) for NE5. Scanning probe microscopy (SPM) study confirms that the droplet size of NE5 was in nanoscale. It can be concluded that the optimized formula (nimodipine NE5) was a promising formula of nanoemulsion to enhance the oral bioavailability of nimodipine.

show abstract

“…The formulation loaded into upper donor compartment is separated from the receptor medium present in the lower compartment by a semipermeable membrane. Franz-diffusion cell was used to assess the drug release properties from numerous formulations aimed for nasal application, such as thermoresponsive soluble gels [55], ion activated in situ gels [56], microparticles [57], nanostructured lipid carriers [58], gel containing microspheres [59], lipidic emulsomes [60], in situ gelling microemulsions [61] and solid lipid nanoparticles [62]. This method is advantageous over other compendial and non-compendial membrane diffusion methods particularly in case of dry powders as it allows them to hydrate slowly, and gel eventually, in humid environment conditions designed to be similar to those encountered in the nasal cavity [63].…”

Section: Membrane Diffusion Methodsmentioning

confidence: 99%